NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Digital Health and Telehealth M&A update, 14–28 September 2026

A bi-weekly read on Digital Health and Telehealth: what moved in the public market, what companies announced, and what changed in the transaction record, for operators, acquirers and advisors tracking the sector week to week.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Digital Health and Telehealth Sector Outlook — September 2026

Key figures

Sector median move
-3.9%
14 covered names, close-to-close
S&P 500 return
+0.8%
same window
Beta Bionics (BBNX) share move
+22.7%
following FDA clearance of Mint patch pump
LifeMD (LFMD) share move
-14.8%
despite carrier distribution collaboration

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIGITAL HEALTH AND TELEHEALTH

Cleared Products Earn a Bid While the Cohort Gives Ground

This update covers what moved, what companies announced, and what changed in the transaction record across Digital Health and Telehealth from September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Digital Health and Telehealth Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Across September 14–28, 2026, the covered cohort broadly declined while the S&P 500 advanced, and the period's gains concentrated in a name that won FDA clearance. A distribution partnership did not prevent a share decline elsewhere, and no material sector transactions were announced. The evidence points to regulatory and operating proof, not announcement volume, as what the market rewarded this period.

Key findings

  • Most covered names fell while the broad market advanced
  • FDA clearance, not guidance alone, drove the period's biggest gain
  • A distribution deal did not stop a share decline elsewhere
  • No new sector transactions; the precedent deal record held steady

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIGITAL HEALTH AND TELEHEALTH

    Cover slide introducing the September 14–28, 2026 Digital Health and Telehealth bi-weekly update.

    We open this bi-weekly update on Digital Health and Telehealth for the two weeks of September 14–28, 2026. The pages that follow walk through what changed, who moved and why, what transacted, and what it means for the people who act on it.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › DIGITAL HEALTH AND TELEHEALTH Cleared Products Earn a Bid While the Cohort Gives Ground This update covers what moved, what companies announced, and what changed in the transaction record across Digital Health and Telehealth from September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Digital Health and Telehealth Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Evidence Moved Value This Period; Announcements on Their Own Did Not

    Summarizes the period's market moves, showing the covered cohort declined while the broad market advanced.

    Across the 14 names we cover, the period's median move was -3.9%, while the S&P 500 returned +0.8% over the same window. We saw evidence — not announcement volume — separate winners from laggards, with a cleared device setting the period's high and a distribution deal failing to hold the line on its own. No material sector transactions were announced, so the visible activity ran through product clearance, partnership and footprint moves. That divergence between operating evidence and market reaction is the theme we carry through the rest of this update.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Evidence Moved Value This Period; Announcements on Their Own Did Not The two-week period in one page · 14 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Digital Health and Telehealth Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 The Cohort Gave Ground While the Broad Market Held 12 of 14 covered names fell; the median move was -3.9%. The S&P 500 returned +0.8% over the same window. 2 A Cleared Device Set the Period's High Beta Bionics, Inc. (BBNX) rose +22.7%, with its biggest single day at +15.3% on Sep 16, following the Sep 14 announcement of FDA clearance for its Mint patch pump. 3 Distribution Reach Did Not Hold the Line on Its Own LifeMD, Inc. (LFMD) fell -14.8% in the window even after announcing an exclusive carrier collaboration that gives eligible customers a membership valued at $228 a year. Enrolment and retention, not eligibility, carry that value. 4 Companies Chose Partnerships over Transactions No material sector transactions were announced during the period. The visible activity ran through product clearance, an integration partnership and a new care site. +22.7% Best mover — Beta Bionics, Inc. (BBNX) worst: EVMN -19.6% · 2 up / 12 down of 14 covered -3.9% Sector median two-week return vs S&P 500 +0.8% 3 Company filings in the window 8-K events read for driver attribution

  3. 03
    PUBLIC MARKET MOVERS

    Regulatory Clearance Paid; Guidance and Pipeline Updates Did Not

    Shows that regulatory clearance was rewarded by the market while guidance and pipeline updates were not.

    We set the materiality bar at ±7.5% on a sector-relative basis, and the period's biggest mover was a company reporting FDA clearance, up +22.7%, with a single-day gain of +15.3%. The sector median fell -3.9%, well behind the S&P 500's +0.8% return over the same window. We link every move only to filings and headlines recorded in the period, and where no driver is recorded, we say so plainly. For operators and advisors, the read is that regulatory proof, not guidance commentary alone, carried the market this period.

    Everything on this page

    PUBLIC MARKET MOVERS Regulatory Clearance Paid; Guidance and Pipeline Updates Did Not Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -3.9% · S&P 500 +0.8% · materiality bar ±7.5% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Digital Health and Telehealth Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -3.9% Beta Bionics, Inc. (BBNX) +22.7% Shares moved following the Sep 14 FDA clearance of the Mint patch pump and an announced partnership pairing year-long continuous glucose monitoring with the iLet Bionic Pancreas. Securities class action filings landed in the same window. A Premium-tier name shows the market pays for cleared product with recurring service attached. COMPANY-SPECIFIC Evommune, Inc. (EVMN) -19.6% Shares moved following the Sep 23 announcement of a late-breaker Phase 2a presentation for EVO301 in atopic dermatitis; the biggest single day, -8.6%, fell on that date, after a Sep 15 filing furnishing an updated corporate presentation. Clinical read-outs reprice adjacent models faster than any contract news in this set. COMPANY-SPECIFIC LifeMD, Inc. (LFMD) -14.8% The available evidence suggests the drag was the downward revenue and EBITDA guidance revision and sequential subscriber decline flagged in Sep 16 coverage, which landed days after the announced carrier collaboration. Reach converts to value through enrolment and retention, not through announcement volume. COMPANY-SPECIFIC Astrana Health, Inc. (ASTH) -11.3% The move appears to reflect the updated investor presentation furnished Sep 15, which carried FY2026 guidance and Q2 2026 revenue of $938.2 million; the biggest day, -9.0%, came Sep 17, with law-firm investigations announced Sep 22. Discount-tier care delivery names are being marked on guidance credibility, not headline revenue. COMPANY-SPECIFIC

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    What Companies Actually Did: Clearance, Distribution and Footprint

    Lists the highest-impact company actions of the period, including clearance, distribution and footprint moves.

    We catalogue the period's highest-impact events, each tied to its filing or article, spanning regulatory clearance, a carrier distribution collaboration and a new care site. Every 'why it matters' line is a NeuraCap read of the recorded evidence rather than an assumption. We hold sources to a fixed reliability order — SEC filings, press releases and established outlets — so the record stays verifiable. This page gives operators and advisors a clean view of what companies actually did, apart from how the market judged it.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS What Companies Actually Did: Clearance, Distribution and Footprint The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Digital Health and Telehealth Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · 8-K · SEC EDGAR Astrana Health set out FY2026 guidance and Q2 results in an updated investor presentation The filing paired FY2026 guidance of $3.8-$4.1 billion Adjusted EBITDA and $255-$280 million revenue with Q2 2026 revenue of $938.2 million. Guidance detail is the price of admission at the discount end of this sector. Sep 15 · 8-K · SEC EDGAR LifeMD struck an exclusive carrier collaboration giving eligible customers a free membership The arrangement opens a large eligible population ahead of a nationwide expansion in January 2027, at a membership value of $228 a year. Whether it counts shows up in activation and cohort retention, not in eligibility. Eligible lives are not enrolled lives; the conversion step is where the value sits. Sep 14 · NEWS · GlobeNewsWire Beta Bionics agreed a partnership integrating year-long glucose monitoring with its iLet system Attaching continuous monitoring to automated insulin delivery widens the recurring service revenue around the device and lifts revenue per user. Device plus recurring service is the attachment model device acquirers underwrite. Sep 14 · NEWS · GlobeNewsWire Beta Bionics won FDA clearance for its Mint patch pump and unveiled a new insulin dosing algorithm Clearance turns a pipeline claim into a sellable product and sets the reimbursement and coding path. It is the evidence the Premium tier of this sector is priced on. Cleared product is the cleanest proof a platform can put in front of payers. Sep 14 · NEWS · Business Wire Concentra opened a new Florida medical center, its first location in Volusia County Site-of-care footprint drives the economics of clinician-heavy models through utilisation and panel size. It extends network reach in a model buyers price on EBITDA. Footprint expansion still sets the pace at the services end of the sector. Sep 14 · NEWS · Business Wire PACS Group took a presenting slot at a September healthcare services and technology conference Putting the operating story in front of the services and technology investor audience signals a Core-tier operator competing for the same attention as platform names. Investor attention in this sector is contested across models, not just within them.

  5. 05
    M&A & STRATEGIC ACTIVITY

    Operators Chose Partnerships While the Precedent Record Held Steady

    Reports that no new sector transactions were announced while the precedent transaction record of 40 deals held steady.

    The precedent transaction record stands at 40 recorded deals, and no material sector transactions were announced during this period. Instead, we saw operators choose partnerships — a clearance paired with a monitoring integration, and a distribution collaboration — over new deal activity. Deal multiples in our record are LTM at announcement where disclosed, and we never re-present old transactions as news. For acquirers, an unchanged precedent record this period means comparables held, even as operating activity moved.

    Everything on this page

    M&A & STRATEGIC ACTIVITY Operators Chose Partnerships While the Precedent Record Held Steady September 14–28, 2026 · precedent transactions: 40 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Digital Health and Telehealth Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. Against 40 trailing precedent transactions, this period's activity ran through product clearance, an integration partnership and a distribution collaboration instead. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 40 Recorded precedent transactions the reference set buyers and sellers price against

  6. 06
    WHAT IT MEANS

    What the Period Changes for Operators, Buyers and Advisors

    Translates the period's evidence into implications for operators, acquirers and advisors.

    We read this period as one where activation and retention, not eligibility alone, decided whose contracts counted for owners and operators. For acquirers, the reference points that shifted were operating ones — a cleared device with a monitoring partnership, a distribution collaboration and a care delivery guidance update — rather than the precedent transaction record, which stayed unchanged. For advisors, the lesson is to lead with proof: clearance, integration partnerships and guidance detail carried value where announcement alone did not. These are our observations on the recorded evidence, not investment recommendations.

    Everything on this page

    WHAT IT MEANS What the Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Digital Health and Telehealth Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 0.8x 15 companies in the study 3 valuation tiers Standing thesis: Digital Health and Telehealth Prices Platforms, Care Delivery and Adjacent Models Differently FOR OWNERS & OPERATORS Activation and Retention Decide Whose Contracts Count Companies in the space that turned eligible populations into enrolled lives and held engagement were the ones the period rewarded. FOR ACQUIRERS The Reference Points That Moved Were Operating Ones The precedent transaction record was unchanged over the window, so the comparisons that shifted came from operations: a cleared device with a monitoring partnership attached, a carrier distribution collaboration, and a care delivery guidance update. FOR ADVISORS Lead with Proof, Not with Announcement Volume The period's theme is that evidence carried value: FDA clearance, integration partnerships and guidance detail.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    Explains the sources and methodology behind the update and states the important notice.

    We build this update from market prices, filings and transaction records through September 28, 2026, with publisher-sourced news linked wherever we cite it. Every figure in this update links back to the record it was taken from, so readers can verify each claim at its source. This closing page sets out how we built the analysis and what each kind of statement in the deck rests on.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Digital Health and Telehealth Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 2 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T171349Z_546_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: sec.gov · globenewswire.com · businesswire.com · newsfilecorp.com · prnewswire.com

Sources and methodology

This update covers Digital Health and Telehealth over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 14 listed companies whose core business is Digital Health and Telehealth under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Akso Health Group (AHG), AMN Healthcare Services, Inc. (AMN), American Well Corporation (AMWL), Astrana Health, Inc. (ASTH), Beta Bionics, Inc. (BBNX), Concentra Group Holdings Parent, Inc. (CON), Evommune, Inc. (EVMN), Hinge Health, Inc. (HNGE), LifeMD, Inc. (LFMD), Omada Health (OMDA), Option Care Health, Inc. (OPCH), PACS Group, Inc. (PACS), Teladoc Health, Inc. (TDOC), WW International, Inc. (WW). 2 names below the floor were excluded from the statistics: DCGO, DRIO.

Window and company universe

This update covers Digital Health and Telehealth over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 14 listed companies whose core business is Digital Health and Telehealth under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Akso Health Group (AHG), AMN Healthcare Services, Inc. (AMN), American Well Corporation (AMWL), Astrana Health, Inc. (ASTH), Beta Bionics, Inc. (BBNX), Concentra Group Holdings Parent, Inc. (CON), Evommune, Inc. (EVMN), Hinge Health, Inc. (HNGE), LifeMD, Inc. (LFMD), Omada Health (OMDA), Option Care Health, Inc. (OPCH), PACS Group, Inc. (PACS), Teladoc Health, Inc. (TDOC), WW International, Inc. (WW). 2 names below the floor were excluded from the statistics: DCGO, DRIO.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Digital Health and Telehealth?

Company valuation reports run the same method against a single business — public or private.